{"entity":{"id":"nct06253130","kind":"trial","name":"A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of IMP1734 in advanced solid tumours, run by Eikon Therapeutics, now recruiting.","summary":"A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06253130 by Eikon Therapeutics, with 156 participants planned, started 2023-12-11 and due to reach its primary completion in 2027-06-01. Interventions recorded: IMP1734.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06253130","url":"https://clinicaltrials.gov/study/NCT06253130"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["eikon-therapeutics","impact-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06253130","phase":"1/2","setting":"A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors","sponsor":"Eikon Therapeutics","enrolled":156,"outcomes":[]},"route":"/trials/nct06253130/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"eikon-therapeutics","kind":"company","name":"Eikon Therapeutics","route":"/companies/eikon-therapeutics/"},{"id":"impact-therapeutics","kind":"company","name":"IMPACT Therapeutics","route":"/companies/impact-therapeutics/"}],"drug":[{"id":"imp1734","kind":"drug","name":"IMP1734","route":"/drugs/imp1734/"}]}}